Page 5 - Fresenius Kabi Acute Care 2017 Product Catalog

Bag Size
100mL
250 mL
500 mL
NDC Code
63323-820-00
63323-820-74
63323-820-50
Bags/Box
10
10
12
Website:
www.smoflipid.com
To Order:
1.888.386.1300
Med Info Phone:
1.800.551.7176 (option 4)
Med Info Email:
nutrition.medinfo.USA@fresenius-kabi.com
DOSAGE FORMS AND STRENGTHS
Smoflipid is a lipid injectable emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 mL.
CONTRAINDICATIONS
• Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the active ingredients or excipients.
• Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides > 1,000 mg/dL.
WARNINGS AND PRECAUTIONS (also see BOXED WARNING)
• Hypersensitivity Reactions: Monitor for signs or symptoms. Discontinue infusion if reactions occur.
• Infection, Fat Overload Syndrome, Refeeding Complications, and Hypertriglyceridemia: Monitor for signs and symptoms; monitor laboratory parameters including serum triglycerides.
• Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants.
• Parenteral Nutrition-Associated Liver Disease: Increased risk in patients who receive parenteral nutrition for extended periods of time, especially preterm infants. Monitor liver function tests, if abnormalities occur consider discontinuation or dosage reduction.
ADVERSE REACTIONS (also see Warnings and Precautions)
Most common adverse drug reactions (>1%) from clinical trials were nausea, vomiting, hyperglycemia, flatulence, pyrexia, abdominal pain, increased blood triglycerides, hypertension, sepsis, dyspepsia, urinary tract infection, anemia and device related infection.
To report SUSPECTED ADVERSE REACTIONS, contact
Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Coumarin and Coumarin Derivatives, Including Warfarin: Anticoagulant activity may be counteracted; monitor laboratory parameters.